Clinical trialNCT06311227RecruitingPhase 2Interventional

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

SponsorNational Cancer Institute (NCI)Enrollment20Recurrent Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia Variant

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert J Kreitman
National Cancer Institute LAO
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope Comprehensive Cancer Center
Duarte, California, United States
Swetha Thiruvengadam
Recruiting
City of Hope at Irvine Lennar
Irvine, California, United States
Swetha Thiruvengadam
Recruiting
Um Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, United States
Justin M. Watts
Recruiting
Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
Justin M. Watts
Recruiting
Um Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, Florida, United States
Justin M. Watts
Recruiting
Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
Justin M. Watts
Recruiting
Um Sylvester Comprehensive Cancer Center at Doral
Doral, Florida, United States
Justin M. Watts
Recruiting
Um Sylvester Comprehensive Cancer Center at Hollywood
Hollywood, Florida, United States
Justin M. Watts
Recruiting
Um Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, United States
Justin M. Watts
Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
Justin M. Watts
Recruiting
University of Kansas Cancer Center
Kansas City, Kansas, United States
Joseph Bennett
Recruiting
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States
Joseph Bennett
Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
Joseph Bennett
Recruiting
University of Maryland/greenebaum Cancer Center
Baltimore, Maryland, United States
Seung Tae Lee
Recruiting
Nci - Center for Cancer Research
Bethesda, Maryland, United States
Robert J. Kreitman
Recruiting
University of Kansas Cancer Center - Briarcliff
Kansas City, Missouri, United States
Joseph Bennett
Recruiting
University of Kansas Cancer Center - North
Kansas City, Missouri, United States
Joseph Bennett
Recruiting
University of Kansas Cancer Center - Lee'S Summit
Lee's Summit, Missouri, United States
Joseph Bennett
Recruiting
University of Cincinnati Cancer Center-Uc Medical Center
Cincinnati, Ohio, United States
Suspended
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Kerry A. Rogers
Recruiting
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, United States
Suspended

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Venetoclax →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Dec 2024
Primary completion: 20 May 2027
Completion: 20 May 2027
Last update posted: 13 Aug 2026
Registered enrollment: 20
Registry id: NCT06311227

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.